CMS certification 380009
Ohsu Hospital and Clinics
3181 SW Sam Jackson Park Road, Portland, OR 97239
Ohsu Hospital and Clinics has a CMS overall rating of 3 out of 5 stars. 76% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. Of the 25 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 3 and worse on 2. Emergency patients spend a median of 3 h 44 min in its emergency department before leaving (US median 2 h 42 min).
Every figure on this page is published by CMS; we arrange and explain it, and score nothing ourselves.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: 812 completed surveys, 24% response rate, Oct 2024 – Sep 2025.
Emergency department
How long emergency patients spent here and how some time-critical care went, from CMS's timely and effective care measures, Oct 2024 – Sep 2025. CMS classes this emergency department's patient volume as high; busier departments tend to have longer times, so the national median for departments of the same volume is shown too. These are medians over a year of visits, not a live wait time.
| Measure | This hospital | OR | US |
|---|---|---|---|
| Median time in the emergency department before leaving Lower is better · 370 visits sampled · US median for EDs of the same volume: 3 h 22 min | 3 h 44 min | 2 h 36 min | 2 h 42 min |
| Median time for psychiatric and mental health patients Lower is better · 25 visits sampled | 4 h 2 min | 3 h 42 min | 4 h 17 min |
| Left before being seen Lower is better · 58,130 patients | 4% | 3% | 2% |
| Severe sepsis and septic shock: all recommended care given Higher is better · 147 patients | 33% | 60% | 65% |
How Ohsu Hospital and Clinics compares with nearby hospitals
The closest hospitals of the same kind that CMS rates or surveys - the same city first, then the same county and ZIP area. Every figure is CMS's: the overall star rating, the share of patients who would definitely recommend the hospital, the median time emergency patients spent before leaving, and how many death, complication, infection and readmission measures CMS found better or worse than the national rate.
| Hospital | CMS stars | Would recommend | ER median time | Vs the nation |
|---|---|---|---|---|
| Ohsu Hospital and ClinicsThis hospital | 3/5 | 76% | 3 h 44 min | 3 better 2 worse |
| Portland VA Medical CenterSame city | 5/5 | 83% | — | 4 better 1 worse |
| Legacy Emanuel Medical CenterSame city | 3/5 | 74% | 2 h 50 min | 1 better 3 worse |
| Providence St Vincent Medical CenterSame city | 4/5 | 79% | 3 h 50 min | 5 better 2 worse |
| Adventist Health PortlandSame city | 4/5 | 71% | 3 h 25 min | 3 better |
| Providence Portland Medical CenterSame city | 4/5 | 77% | 3 h 35 min | 3 better |
Hospitals differ in size and in how sick their patients are. CMS adjusts its outcome measures for that, but a star or a percentage is a starting point for questions, not a verdict. All hospitals in Portland.
Deaths
How many patients died within 30 days of admission, adjusted by CMS for how sick they were. Lower is better. Data from Jul 2022 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| All patients, hospital-wide 3,434 cases | Too few cases | 3.4% | 3.9% |
| Heart attack 98 cases | Too few cases | 11.3% | 11.9% |
| Heart failure 197 cases | Too few cases | 10.6% | 11.1% |
| Pneumonia 145 cases | Too few cases | 14.7% | 15.2% |
| Stroke 273 cases | Too few cases | 11.7% | 11.9% |
| Heart bypass surgery (CABG) 44 cases | Too few cases | 3% | 2.4% |
1 more measure had too few cases here to report.
Complications
How often patients had serious complications, most of them after surgery, adjusted for how sick they were. Lower is better. Data from Jul 2022 – Jun 2024.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Serious complications, combined measure | Worse | 1.31 likely 1.1 – 1.51 | 1 |
| After hip or knee replacement 56 cases | Too few cases | 4.2% | 4.1% |
| Deaths after a serious but treatable surgical complication 340 cases | No different | 150.45 per 1,000 likely 118.94 per 1,000 – 181.96 per 1,000 | 173.3 per 1,000 |
| Pressure ulcers (bed sores) 6,661 cases | No different | 0.66 per 1,000 likely 0.18 per 1,000 – 1.14 per 1,000 | 0.63 per 1,000 |
| Collapsed lung caused by a procedure 7,501 cases | No different | 0.25 per 1,000 likely 0.07 per 1,000 – 0.43 per 1,000 | 0.21 per 1,000 |
| Broken bones from falls in the hospital 7,980 cases | No different | 0.24 per 1,000 likely 0.06 per 1,000 – 0.42 per 1,000 | 0.27 per 1,000 |
| Bleeding or hematoma after surgery 3,615 cases | No different | 2.27 per 1,000 likely 1.24 per 1,000 – 3.31 per 1,000 | 2.34 per 1,000 |
| Kidney injury needing dialysis after surgery 2,337 cases | No different | 2.42 per 1,000 likely 1.27 per 1,000 – 3.57 per 1,000 | 1.67 per 1,000 |
| Breathing failure after surgery 2,153 cases | No different | 10.99 per 1,000 likely 7.55 per 1,000 – 14.42 per 1,000 | 9.42 per 1,000 |
| Blood clots in the lungs or legs after surgery 3,784 cases | Worse | 6.83 per 1,000 likely 5.37 per 1,000 – 8.29 per 1,000 | 3.52 per 1,000 |
| Sepsis after surgery 2,355 cases | No different | 7.35 per 1,000 likely 5.23 per 1,000 – 9.48 per 1,000 | 5.27 per 1,000 |
| Surgical wound splitting open 1,001 cases | No different | 1.98 per 1,000 likely 0.69 per 1,000 – 3.27 per 1,000 | 1.77 per 1,000 |
| Accidental cut or tear during abdominal surgery 2,275 cases | No different | 1.38 per 1,000 likely 0.61 per 1,000 – 2.14 per 1,000 | 1.06 per 1,000 |
Infections caught in the hospital
Standardized infection ratio: 1.0 means as many infections as CMS predicted for a hospital like this one. Lower is better. Data from Oct 2024 – Sep 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Bloodstream infections from central lines (CLABSI) | No different | 0.8 likely 0.57 – 1.1 | 1 |
| Urinary tract infections from catheters (CAUTI) | No different | 0.84 likely 0.59 – 1.16 | 1 |
| Surgical site infections after colon surgery | No different | 1.17 likely 0.64 – 2 | 1 |
| Surgical site infections after abdominal hysterectomy | No different | 1.38 likely 0.44 – 3.33 | 1 |
| MRSA bloodstream infections | No different | 0.94 likely 0.56 – 1.47 | 1 |
| C. diff intestinal infections | Better | 0.73 likely 0.59 – 0.91 | 1 |
Readmissions and return visits
How often patients had to come back to a hospital after going home. Lower is better. Data from Jul 2023 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Readmitted after a heart attack 180 cases | Too few cases | 14.7% | 14.4% |
| Readmitted after heart failure 320 cases | Too few cases | 20.3% | 21.3% |
| Readmitted after pneumonia 204 cases | Too few cases | 15.6% | 17.3% |
| Readmitted after COPD 49 cases | Too few cases | 19.6% | 20% |
| Readmitted after heart bypass surgery 88 cases | Too few cases | 9.4% | 11% |
| Readmitted after hip or knee replacement 47 cases | Too few cases | 5.8% | 5.8% |
| Days back in hospital after a heart attack 120 cases | Too few cases | 11.9 days per 100 | — |
| Days back in hospital after heart failure 223 cases | Too few cases | 7.9 days per 100 | — |
| Days back in hospital after pneumonia 142 cases | Too few cases | 24.5 days per 100 | — |
| Unplanned visits after an outpatient colonoscopy 1,483 cases | No different | 11.8 per 1,000 likely 9.1 per 1,000 – 15.4 per 1,000 | 13 per 1,000 |
| Hospital admissions during outpatient chemotherapy 952 cases | No different | 9.5 per 100 likely 8 per 100 – 11.4 per 100 | 10.7 per 100 |
| ER visits during outpatient chemotherapy 952 cases | No different | 5 per 100 likely 3.9 per 100 – 6.3 per 100 | 5.4 per 100 |
| Unplanned visits after outpatient surgery 1,425 cases | No different | 0.9 likely 0.7 – 1.1 | — |
1 more measure had too few cases here to report.
Clinicians registered at this address
3,192 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry, plus 1,054 residents and trainees. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Emergency Medicine | 161 |
| Anesthesiology | 152 |
| Pediatrics | 128 |
| Medical | 124 |
| Internal Medicine | 119 |
| Nurse Anesthetist, Certified Registered | 113 |
| Diagnostic Radiology | 104 |
| Hospitalist | 98 |
| Clinical | 97 |
| Psychiatry | 92 |
| Family Medicine | 85 |
| Acute Care | 70 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $35.4M
- 2020 $37.4M
- 2021 $35.2M
- 2022 $27.7M
- 2023 $31.7M
- 2024 $32M
- 2025 $40M
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Grants | $550,188 | 30 |
| Speaking, teaching and other services | $519,504 | 121 |
| Royalties and licensing fees | $177,983 | 6 |
| Space rental and facility fees | $155,703 | 65 |
| Consulting fees | $93,133 | 28 |
| Medical devices and supplies on long-term loan | $33,011 | 5 |
| Faculty and speaker fees for medical education | $15,000 | 2 |
| Education | $12,552 | 2 |
| Charitable contributions | $500 | 1 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Janssen Research & Development, LLC | $3.6M | 199 |
| Merck Sharp & Dohme LLC | $3.5M | 46 |
| Abbvie INC. | $3.4M | 168 |
| AstraZeneca Pharmaceuticals LP | $2.8M | 28 |
| Regeneron Pharmaceuticals, Inc. | $2.7M | 202 |
| Deciphera Pharmaceuticals Inc. | $2M | 157 |
| Edwards Lifesciences Corporation | $1.3M | 58 |
| Amgen Inc. | $1M | 19 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| A STUDY OF RIPRETINIB VS SUNITINIB IN PATIENTS WITH ADVANCED GIST WITH SPECIFIC KIT EXON MUTATIONS WHO WERE PREVIOUSLY TREATED WITH IMATINIB (INSIGHT) Deciphera Pharmaceuticals Inc. · NCT05734105 | $873,160 |
| A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCI… Deciphera Pharmaceuticals Inc. | $841,642 |
| An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatini… Merck Sharp & Dohme LLC | $818,331 |
| Ecologically Valid, Ambient, Longitudinal and Unbiased Assessment of Treatment Efficacy in Parkinson's Disease ABBVIE INC. | $750,000 |
| A Phase 1b Dose Escalation Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with … Janssen Research & Development, LLC | $727,569 |
| A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in P… Astellas Pharma Global Development | $704,499 |
| Follow-up Study of a vector for the Treatment of X-Iinked Retinitis Pigmentosa Associated with Variants in the RPGR gene Janssen Research & Development, LLC | $645,111 |
| A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation Astellas Pharma Inc | $567,996 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about Ohsu Hospital and Clinics
Is Ohsu Hospital and Clinics a good hospital?
Ohsu Hospital and Clinics has a CMS overall rating of 3 out of 5 stars. Of the 25 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 3 and worse on 2. These are hospital-wide results published by CMS; they do not rate individual doctors or departments.
Would patients recommend Ohsu Hospital and Clinics?
76% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. The figure comes from 812 completed HCAHPS surveys.
How long is the wait in the Ohsu Hospital and Clinics emergency room?
Emergency patients spend a median of 3 h 44 min in its emergency department before leaving (US median 2 h 42 min). Among US emergency departments with high patient volume, like this one, the median is 3 h 22 min. 4% of emergency patients left before being seen (US 2%). These are medians over a year of visits, not a live wait time.
Does Ohsu Hospital and Clinics receive money from drug and device companies?
Drug and device makers reported $40M in payments to Ohsu Hospital and Clinics for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.